From flamingo dance to (desirable) drug discovery: a nature-inspired approach.

The therapeutic effects of drugs are well known to result from their interaction with multiple intracellular targets. Accordingly, the pharma industry is currently moving from a reductionist approach based on a 'one-target fixation' to a holistic multitarget approach. However, many drug discovery practices are still procedural abstractions resulting from the attempt to understand and address the action of biologically active compounds while preventing adverse effects. Here, we discuss how drug discovery can benefit from the principles of evolutionary biology and report two real-life case studies. We do so by focusing on the desirability principle, and its many features and applications, such as machine learning-based multicriteria virtual screening.

[1]  Alexander Tropsha,et al.  Best Practices for QSAR Model Development, Validation, and Exploitation , 2010, Molecular informatics.

[2]  Andrew T Maynard,et al.  Quantifying, Visualizing, and Monitoring Lead Optimization. , 2016, Journal of medicinal chemistry.

[3]  Maykel Cruz-Monteagudo,et al.  Desirability-based multi-objective QSAR in drug discovery. , 2012, Mini reviews in medicinal chemistry.

[4]  Byung Rae Cho,et al.  Quality by Design Studies on Multi-response Pharmaceutical Formulation Modeling and Optimization , 2012, Journal of Pharmaceutical Innovation.

[5]  Angelo Carotti,et al.  Strategies of multi-objective optimization in drug discovery and development , 2011, Expert opinion on drug discovery.

[6]  Maykel Cruz-Monteagudo,et al.  Chemoinformatics profiling of ionic liquids--automatic and chemically interpretable cytotoxicity profiling, virtual screening, and cytotoxicophore identification. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[7]  J. Irwin,et al.  Benchmarking sets for molecular docking. , 2006, Journal of medicinal chemistry.

[8]  Michael Wink,et al.  Modes of Action of Herbal Medicines and Plant Secondary Metabolites , 2015, Medicines.

[9]  V. Acharya,et al.  A systematic approach to prioritize drug targets using machine learning, a molecular descriptor-based classification model, and high-throughput screening of plant derived molecules: a case study in oral cancer. , 2015, Molecular bioSystems.

[10]  Angelo Carotti,et al.  Neuronal nicotinic acetylcholine receptor agonists: pharmacophores, evolutionary QSAR and 3D-QSAR models. , 2004, Current topics in medicinal chemistry.

[11]  Fuhui Long,et al.  Feature selection based on mutual information criteria of max-dependency, max-relevance, and min-redundancy , 2003, IEEE Transactions on Pattern Analysis and Machine Intelligence.

[12]  Subhash C. Bagui,et al.  Combining Pattern Classifiers: Methods and Algorithms , 2005, Technometrics.

[13]  Johan A. K. Suykens,et al.  Least Squares Support Vector Machines , 2002 .

[14]  José L. Medina-Franco,et al.  Research Highlights : We introduce a new concept , the systemic chemogenomics / QSAR , 2017 .

[15]  D. Cummins,et al.  Integrating Everything: The Molecule Selection Toolkit, a System for Compound Prioritization in Drug Discovery. , 2016, Journal of medicinal chemistry.

[16]  Peter J. Fleming,et al.  Combinatorial Library Design Using a Multiobjective Genetic Algorithm , 2002, J. Chem. Inf. Comput. Sci..

[17]  Alexander Golbraikh,et al.  Combinatorial QSAR Modeling of P-Glycoprotein Substrates , 2006, J. Chem. Inf. Model..

[18]  R. Polikar,et al.  Ensemble based systems in decision making , 2006, IEEE Circuits and Systems Magazine.

[19]  Prabha Garg,et al.  Selective Fusion of Heterogeneous Classifiers for Predicting Substrates of Membrane Transporters , 2017, J. Chem. Inf. Model..

[20]  Robert Alan Goodnow.  Industrialization of Drug Discovery: From Target Selection Through Lead Optimization. Edited by Jeffrey S. Handen. , 2006 .

[21]  U. Maran,et al.  Molecular property filters describing pharmacokinetics and drug binding. , 2012, Current medicinal chemistry.

[22]  Patrick O. Brown,et al.  Directed Chemical Evolution with an Outsized Genetic Code , 2016, PloS one.

[23]  Maykel Cruz-Monteagudo,et al.  Ligand-Based Virtual Screening Using Tailored Ensembles: A Prioritization Tool for Dual A2AAdenosine Receptor Antagonists / Monoamine Oxidase B Inhibitors. , 2016, Current pharmaceutical design.

[24]  Valerie J. Gillet,et al.  Evaluation of reactant-based and product-based approaches to the design of combinatorial libraries , 2000 .

[25]  Bruno Boulanger,et al.  A Fast Exchange Algorithm for Designing Focused Libraries in Lead Optimization. , 2005 .

[26]  G. Mangiatordi,et al.  Applicability Domain for QSAR models: where theory meets reality , 2016 .

[27]  G. Derringer,et al.  Simultaneous Optimization of Several Response Variables , 1980 .

[28]  Reinaldo Molina Ruiz,et al.  Desirability-based methods of multiobjective optimization and ranking for global QSAR studies. Filtering safe and potent drug candidates from combinatorial libraries. , 2008, Journal of combinatorial chemistry.

[29]  Maykel Cruz-Monteagudo,et al.  Prioritizing Hits with Appropriate Trade‐Offs Between HIV‐1 Reverse Transcriptase Inhibitory Efficacy and MT4 Blood Cells Toxicity Through Desirability‐Based Multiobjective Optimization and Ranking , 2010, Molecular informatics.

[30]  Angelo Carotti,et al.  Improving Quantitative Structure-Activity Relationships through Multiobjective Optimization , 2009, J. Chem. Inf. Model..

[31]  Maykel Cruz-Monteagudo,et al.  Activity cliffs in drug discovery: Dr Jekyll or Mr Hyde? , 2014, Drug discovery today.

[32]  Matthew D. Segall,et al.  The challenges of making decisions using uncertain data , 2015, Journal of Computer-Aided Molecular Design.

[33]  R. Pradel,et al.  Sexual display complexity varies non-linearly with age and predicts breeding status in greater flamingos , 2016, Scientific Reports.

[34]  Julie Clark,et al.  Discovery of Novel Antimalarial Compounds Enabled by QSAR-Based Virtual Screening , 2013, J. Chem. Inf. Model..

[35]  Emilio Benfenati,et al.  An alternative QSAR-based approach for predicting the bioconcentration factor for regulatory purposes. , 2014, ALTEX.

[36]  Kunal Roy,et al.  A review on principles, theory and practices of 2D-QSAR. , 2014, Current drug metabolism.

[37]  Mark C. Fishman,et al.  Pharmaceuticals: A new grammar for drug discovery , 2005, Nature.

[38]  Angelo Carotti,et al.  An Integrated Approach to Ligand- and Structure-Based Drug Design: Development and Application to a Series of Serine Protease Inhibitors , 2008, J. Chem. Inf. Model..

[39]  C George,et al.  A Balancing Act: Optimizing a Product's Properties , 1994 .

[40]  Valerie J Gillet,et al.  Multiobjective optimization in quantitative structure-activity relationships: deriving accurate and interpretable QSARs. , 2002, Journal of medicinal chemistry.

[41]  G. V. Paolini,et al.  Quantifying the chemical beauty of drugs. , 2012, Nature chemistry.

[42]  Christopher I. Bayly,et al.  Evaluating Virtual Screening Methods: Good and Bad Metrics for the "Early Recognition" Problem , 2007, J. Chem. Inf. Model..

[43]  J Willem M Nissink,et al.  Analyzing compound and project progress through multi-objective-based compound quality assessment. , 2013, Future medicinal chemistry.

[44]  Matthew Segall,et al.  Advances in multiparameter optimization methods for de novo drug design , 2014, Expert opinion on drug discovery.

[45]  Joelle M. R. Gola,et al.  Focus on success: using a probabilistic approach to achieve an optimal balance of compound properties in drug discovery , 2006, Expert opinion on drug metabolism & toxicology.

[46]  Nanda Ghoshal,et al.  Rationalizing fragment based drug discovery for BACE1: insights from FB-QSAR, FB-QSSR, multi objective (MO-QSPR) and MIF studies , 2010, J. Comput. Aided Mol. Des..

[47]  Nathan Brown,et al.  Molecular optimization using computational multi-objective methods. , 2007, Current opinion in drug discovery & development.

[48]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[49]  Alexander Tropsha,et al.  Trust, but Verify II: A Practical Guide to Chemogenomics Data Curation , 2016, J. Chem. Inf. Model..

[50]  Jason Micklefield,et al.  Mining and engineering natural-product biosynthetic pathways. , 2007, Nature chemical biology.

[51]  Nathan Brown,et al.  Multi-objective optimization methods in drug design. , 2013, Drug discovery today. Technologies.

[52]  Jeffrey S. Handen.  Industrialization of Drug Discovery : From Target Selection Through Lead Optimization , 2005 .

[53]  M. Natália D. S. Cordeiro,et al.  Desirability‐based multiobjective optimization for global QSAR studies: Application to the design of novel NSAIDs with improved analgesic, antiinflammatory, and ulcerogenic profiles , 2008, J. Comput. Chem..

[54]  Shane Weaver,et al.  The importance of the domain of applicability in QSAR modeling. , 2008, Journal of molecular graphics & modelling.

[55]  Nuno Ricardo Costa,et al.  Desirability function approach: A review and performance evaluation in adverse conditions , 2011 .